Research papers unicorn

The company is currently researching new potential therapies for ALS and has one clinical trial planned for next year with a new molecule designed in-house. “When we ran the query about ALS, our system came back with a rank list of hypotheses,” says Hunter. “The system isn't 100% right all the time, so the end result is really a combination of the platform and the insight of the scientists.” In the case of ALS, BenevolentAI picked five new compounds and tested on cell cultures with motor neurone disease. “One failed the test, three worked as well as current gold standard and one worked exceptionally well,” Hunter says. “We have an end-to-end organisation capable to doing very basic, exploratory science right the way through clinical trials.”